40 R&D researchers after a major launch

This case is an anonymised composite of two engagements with a top-20 global pharmaceutical company and one mid-cap biotech firm. The programme was run for the R&D org after the major launch of an oncology therapeutic. Company names and the drug name are withheld under NDA; the retention and pipeline metrics are original. We also regularly use some of the operational details from this programme in other engagements for pharma R&D teams, as a reference methodology for recovery after a major launch.

Context

The client

A global pharmaceutical company with its R&D headquarters in Basel and two further research centres, in Boston and Barcelona. The R&D org is 850 people, 240 of them lead researchers holding a PhD or MD. The target cohort for the programme was 40 senior researchers who had run the drug launch project directly from Phase II clinical trial to regulatory approval — 38 PhDs and two MDs, with an average tenure of 12 years and an average age of 47.

The pain

A major drug launch is four years of intense work, alternating sprint periods before a regulatory submission with pauses waiting on the regulator's decision. After approval the team goes through post-launch deflation — a known phenomenon in pharma R&D that usually shows up in two waves. The first, expected wave is two or three lead researchers leaving for competitors within six months, actively headhunted because a launch validates their market value. The second, less expected wave is a drop in the creative output of the remaining team over 9 to 12 months. The Chief Scientific Officer came to us with a brief: "break post-launch deflation without breaking discipline."

Why us

Discovery took eight weeks — the longest in our practice. The CSO met us three times, and we also held calls with four team leads and the corporate medical-ethics board, because pharma R&D follows strict guidance on non-conference activities. We proposed a five-day Sicily to Mallorca cruise as a format that is structurally the opposite of a conference: on the water, in motion, no slides and no structured agenda for the first three days. The CSO agreed on one condition — the final day had to give him "one whiteboard worth of next-cycle ideas." The contract was signed nine weeks into discovery.

What we did

Photos from the programme

Lessons

• For pharma R&D, decompression has to be real and physical — three days with no structure. Every past attempt to wedge a work block into day one ended with the team unable to switch out of post-launch mode. Three days with no agenda is not a luxury, it is a mandatory part of the protocol.
• The age profile calls for a structurally different format from a fintech programme. Senior researchers over 50 prefer cruising with minimal physical exertion. A regatta does not suit this cohort. SUP, snorkelling in sheltered bays, swimming and evening dinners with structured reflection formats do.
• A whiteboard on deck is an operational must. Pharma R&D thinking is structured through visual diagrams — pathways, mechanisms of action. A closing session without a whiteboard would have been wasted time.
• A psychologist in a shadow role — not as an active facilitator — proved more valuable than we expected. After the trip three researchers approached him for coaching engagements, which the company supported through an HR partnership. That turned into long-term support that had not existed before the offsite.

Financial breakdown

The budget for 40 participants over 5 days was €165,000 excluding flights. Per participant that was €4,125 — meaningfully above our average, because a five-day cruise with long passages needs more capacity: a fresh crew, more fuel and moored stays in the marinas of two different countries. The split: charter — 39 %; pre- and post-event accommodation in two five-star hotels — 22 %; catering and provisioning — 14 %; programme (a shadow psychologist plus two facilitators for the finale) — 9 %; medical support and safety — 5 %; logistics and transfers — 5 %; insurance — 3 %; contingency — 3 %.

Corporate-ethics compliance

Pharma R&D is an org where every non-conference activity involving senior researchers passes through corporate compliance. The logic is simple: researchers have relationships with suppliers of laboratory equipment, reagents and clinical trial sites, and any activity that might look like "a reward for good relations" needs transparent documentation. We prepared a separate compliance pack for this engagement: a formal justification of the "scientific retreat" format with citations to academic sources on post-launch team dynamics, a transparent budget and an independent value-per-participant assessment against standard conference formats.

The client's compliance team ran its own analysis and approved the programme as a category-B "professional development activity", meaning the cost was booked as an HR investment rather than a separate benefit. That is a critical jurisdictional point — without the right classification the programme would have created compliance risk for the participants.

Twelve months later

This is the longest post-event tracking in our practice — we usually do a 90-day recheck. For pharma R&D a 12-month horizon is the relevant metric, because post-launch deflation plays out over that interval. A year on, the CSO ran a retrospective: 39 of the 40 programme participants remained in the company's R&D org. Of the 12 candidate research directions that passed first internal review, four were funded for full clinical exploration with a budget allocation. Those four projects are potential new product lines on a six-to-eight-year horizon. The offsite paid for itself as an investment vehicle, not as an event.

On top of that, over the following year the company built six similar internal retreats for other R&D orgs around our format, using our programme as a reference. One of them — for the cardiovascular research team after a Phase III trial readout — ran in Croatia in May 2025. We did not work with the company on that second programme directly (it was handed to a local Croatian team they were recommended), but the methodology, documentation and compliance pack were ours. It is a non-standard success metric, but it shows the offsite has stopped being an event and become a durable corporate instrument.

Eighteen months after the programme the CSO sent us a short note: "Thank you. This was the best investment R&D made during my tenure. When I retire in two years, I will try to leave this methodology in the DNA of the organisation." That is not a testimonial for marketing — it is an operational outcome showing the format works over a long horizon and outlasts individual leaders.

A final important nuance is psychological safety on the water. For high-level R&D researchers it matters not to look incompetent in front of colleagues. We ran a sailing induction in Palermo for all 40 participants in advance so everyone had the basic skills aboard. On the water this created an atmosphere where nobody felt nervous about not knowing the sailing terminology, and the discussions ran without extra social stress — which matters for creative work.